Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Myofascial Temporomandibular Disorder
NCT02202070Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in temporomandibular joint disorder (TMJ) (2 arms), sponsored by Washington University School of Medicine. Primary endpoint: 50% reduction in pain at 6 months. Planned start Jan 2015; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular joint disorder (TMJ)
Beyond the preview
Go deeper on NCT02202070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202070.